🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  2. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (pfs) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  3. Sorafenib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 3 small molecule active

    2 trials

  4. Sovateltide, Sovateltide matching placebo

    Lacuna Pharma Pty Ltd

    Acute cerebral ischemic stroke

    phase 3 small molecule active

    1 trial

  5. Spesolimab i.v.

    Boehringer Ingelheim

    Hidradenitis Suppurativa

    phase 3 small molecule completed

    1 trial

  6. Spesolimab, Placebo matching to Spesolimab

    Boehringer Ingelheim

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  7. Spravato 28 mg nasal spray, solution, Midazolam-ratiopharm® 2 mg/ml orale Lösung, Oral placebo, Intranasal Placebo

    Janssen-Cilag International N.V.

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  8. Standard Care Intervention (SCI)

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Dependence

    phase 3 other completed

    1 trial

  9. Standard First-Line Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unresectable Colorectal Cancer

    phase 3 small molecule active

    1 trial

  10. Start antiplatelet monotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Intracerebral Hemorrhage

    phase 3 small molecule completed

    1 trial

  11. Sterile 0.9% (w/v) sodium chloride solution in single-use PFS, Novolizer Salbutamol 100 microgrammes/dose, poudre pour inhalation

    GlaxoSmithKline

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  12. Sterile normal saline (0.9% sodium chloride solution), ADX-324

    Lacuna Pharma Pty Ltd

    Hereditary Angioedema

    phase 3 small molecule active

    1 trial

  13. Steroid nasal spray

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Radiation-Induced Mucositis

    phase 3 small molecule active

    1 trial

  14. Stimus (NNG-DEPO)

    Biotech Pharmaceutical Co.,

    Anemia

    phase 3 mab completed

    1 trial

  15. Subcutaneous Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Metastatic Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  16. Sublingual film containing Dexmedetomidine (BXCL501)

    BioXcel Therapeutics

    Agitation Associated With Bipolar Disorder

    phase 3 small molecule completed

    1 trial

  17. Sublingual film containing dexmedetomidine (BXCL501)

    BioXcel Therapeutics

    Agitation

    phase 3 small molecule completed

    1 trial

  18. Subxiphoid uniportal VATS

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Neoplasms

    phase 3 other completed

    1 trial

  19. Subxiphoid uniportal VATS

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mediastinal Neoplasms

    phase 3 other active

    1 trial

  20. Sufentanil Mylan 50 microgrammes/ml solution injectable, MORPHINE HYDROCHLORIDE, CHLORURE DE SODIUM 0,9 % LAVOISIER, solution pour perfusion

    Pari Pharma GmbH

    vaso-occlusive crisis due to sickle cell disease

    phase 3 small molecule active

    1 trial

  21. Sugammadex 100 mg/ml solution for injection, Rocuronium bromide 10 mg/ml solution for injection/infusion

    Istituto Gentili S.r.l.

    patients scheduled to undergo elective surgical procedures with general anesthesia

    phase 3 small molecule active

    1 trial

  22. Supportive care+Prednisone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Minimal Change Disease

    phase 3 small molecule active

    1 trial

  23. Suprefact Depot 9,45 mg implantat, Pamorelin 11,25 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Pamorelin 22,5 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Pamorelin 3,75 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Eligard 45 mg poeder en oplosmiddel voor oplossing voor injectie, LEUPRORELIN ACETATE, CAMCEVI 42 mg prolonged-release suspension for injection, Gonapeptyl Depot 3,75 mg poeder en oplosmiddel

    Disc Medicine

    low-volume metastatic castration-sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  24. Sutent 50 mg hard capsules, Alectinib (Alecensa), Sutent 12.5 mg hard capsules, Cotellic, Sutent 25 mg hard capsules, RO7047650, Cotellic, Alecensa 150 mg hard capsules, Tecentriq 1 200 mg concentrate for solution for infusion, Zelboraf, Sutent 12.5 mg hard capsules, Venclexta, Venclyxto, Alecensa 150 mg hard capsules, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, RO7250726, Sutent 25 mg hard capsules, ALIMTA 500 mg powder for concentrate for solution for infusion, Sutent 50 mg hard capsules, Ze

    Hoffmann-La Roche

    Advanced Malignancies

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources